(NASDAQ GS: NTRA)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Natera, Inc. ("Natera" or the "Company") on behalf of stockholders. A class action complaint has been filed against Natera. The complaint alleges that defendants misrepresented and/or failed to disclose that: (i) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (ii) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (iii) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (iv) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (v) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.